Intensity Therapeutics Q2 net loss widens as R&D costs rise

Intensity Therapeutics

11/08/2026 12:38

Overview
US cancer therapy developer's Q2 net loss widened yr/yr as R&D expenses increased
Company restarted patient treatment in Phase 2 TNBC trial and resumed Phase 3 sarcoma study activities
Raised $1.6 mln in net proceeds under ATM facility; cash stood at $9.5 mln end-Q2

Outlook
Company expects to resume U.S. enrollment in INVINCIBLE-3 Phase 3 study by Q3 2026
Company targets complete enrollment in INVINCIBLE-4 Phase 2 study by end of 2027
Company expects to continue strategic partnership discussions in second half of 2026

Result Drivers
CLINICAL TRIAL RESUMPTION - Increased R&D expenses driven by resumed activities in Phase 3 INVINCIBLE-3 sarcoma study
TRIAL PROTOCOL MODIFICATIONS - Protocol amendments in TNBC and sarcoma trials followed investigator feedback and regulatory review
PRELIMINARY TRIAL DATA - Early results in Phase 2 TNBC trial showed higher pathological complete response rates and fewer adverse events

Company press release: ID:nPn5kKXwYa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Basic Share
 
$1.11
 
Q2 Operating Income
 
-$3.08 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Intensity Therapeutics Inc is $30.00, about 599.3% above its August 10 closing price of $4.29

Reuters Recommended Reads
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 11 - Shattuck Labs Q2 net loss widens as R&D spending rises
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)